These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25197828)

  • 1. Risk reduction with buprenorphine-naloxone and methadone: patient's choice.
    Newman RG
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):e142. PubMed ID: 25197828
    [No Abstract]   [Full Text] [Related]  

  • 2. Authors' reply: "Risk reduction with buprenorphine-naloxone and methadone: patient's choice".
    Woody G; Bruce D; Korthuis PT; Chhatre S; Hillhouse M; Jacobs P; Sorensen J; Saxon AJ; Poole S; Metzger D; Ling W
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):e142-3. PubMed ID: 25243431
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
    Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
    Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.
    Woody GE; Bruce D; Korthuis PT; Chhatre S; Poole S; Hillhouse M; Jacobs P; Sorensen J; Saxon AJ; Metzger D; Ling W
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):288-93. PubMed ID: 24751432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
    Chaudhry AA; Botsko M; Weiss L; Egan JE; Mitty J; Estrada B; Lucas GM; Woodson T; Flanigan TP; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S14-21. PubMed ID: 21317589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of buprenorphine for substance-abuse treatment by HIV care providers.
    Friedland G; Vlahov D
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S1-2. PubMed ID: 21317588
    [No Abstract]   [Full Text] [Related]  

  • 9. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
    Saunders EC
    Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
    [No Abstract]   [Full Text] [Related]  

  • 12. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
    Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
    Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Opioid Overdose.
    Babu KM; Brent J; Juurlink DN
    N Engl J Med; 2019 Jun; 380(23):2246-2255. PubMed ID: 31167053
    [No Abstract]   [Full Text] [Related]  

  • 15. [Is the availability of buprenorphine/naloxone therapy for opioid-dependent inmates a necessity? ].
    Marco A; López-Burgos A; García-Marcos L; Gallego C; Antón JJ; Errasti A
    Rev Esp Sanid Penit; 2013 Feb; 15(3):105-13. PubMed ID: 24270319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of opioid dependence with buprenorphine: current update.
    Soyka M
    Dialogues Clin Neurosci; 2017 Sep; 19(3):299-308. PubMed ID: 29302227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment.
    Weiss L; Egan JE; Botsko M; Netherland J; Fiellin DA; Finkelstein R
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S7-13. PubMed ID: 21317598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 20. Narrative review: buprenorphine for opioid-dependent patients in office practice.
    Sullivan LE; Fiellin DA
    Ann Intern Med; 2008 May; 148(9):662-70. PubMed ID: 18458279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.